Expression of interleukin-6 is associated with epithelial-mesenchymal transition and survival rates in gallbladder cancer

Zhang,Mingdi; Gong,Wei; Zhang,Yong; Yang,Yong; Zhou,Di; Weng,Mingzhe; Qin,Yiyu; Jiang,Alex; Ma,Fei; Quan,Zhiwei

doi:10.3892/mmr.2014.3143

Expression of interleukin-6 is associated with epithelial-mesenchymal transition and survival rates in gallbladder cancer

Authors:
- Mingdi Zhang
- Wei Gong
- Yong Zhang
- Yong Yang
- Di Zhou
- Mingzhe Weng
- Yiyu Qin
- Alex Jiang
- Fei Ma
- Zhiwei Quan
View Affiliations

Affiliations: Department of General Surgery, Xinhua Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200092, P.R. China, Department of Health Science, Schulich School of Medicine and Dentistry, Western Ontario University, London, ON N6A 3K6, Canada, Department of Oncology, Xinhua Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200092, P.R. China
Published online on: December 31, 2014 https://doi.org/10.3892/mmr.2014.3143
Pages: 3539-3546

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression of interleukin‑6 (IL‑6) in gallbladder cancer (GBC) tissues and its correlation with survival rate. The association between IL‑6 and epithelial‑mesenchymal transition (EMT)‑associated markers was also examined. Using immunohistochemistry, reverse transcription quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis, the protein and mRNA expression levels of IL‑6, Twist, E‑cadherin and Vimentin in 20 GBC tissues were analyzed. The IL‑6, Twist and Vimentin proteins were overexpressed in 40, 20 and 70% of the human GBC samples, respectively. The protein expression of E‑cadherin was higher in only 5% of the GBC samples. These differences were significant (P<0.05). Western blot analysis also revealed overexpression of IL‑6, Twist and Vimentin and underexpression of E‑cadherin in the GBC samples with poor differentiation, local invasion and a higher tumor‑node‑metastasis (TNM) stage (P<0.05). Higher mRNA expression levels of IL‑6, Twist and Vimentin and a reduced expression level of E‑cadherin were also demonstrated in the GBC tissues (P<0.05). The degree of differentiation, local invasion, lymph node metastasis and clinical stage were significantly associated with the mRNA expression levels of IL‑6, Twist and E‑cadherin. The increased expression levels of IL‑6 and Twist and the reduced expression of E‑cadherin correlated with shorter median survival rates (P<0.05). Line regression results revealed correlation among the mRNA expression levels of IL‑6, Twist, E‑cadherin and Vimentin. To the best of our knowledge, the present study is the first to demonstrate that IL‑6 is associated with EMT‑associated markers, tumor differentiation, local invasion, TNM stage and survival rates in GBC.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008v2.0: Cancer incidence and mortality worldwide. IARC CancerBase No. 10 Lyon, France: International Agency for Research on Cancer; 2010, http://globocan.iorc.fr. Accessed August 2012
2	Alvi AR, Siddiqui NA and Zafar H: Risk factors of gallbladder cancer in Karachi-a case-control study. World J Surg Oncol. 9:1642011. View Article : Google Scholar : PubMed/NCBI
3	Reid KM, Ramos-De la Medina A and Donohue JH: Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg. 11:671–681. 2007. View Article : Google Scholar : PubMed/NCBI
4	Hundal R and Shaffer EA: Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 6:99–109. 2014.PubMed/NCBI
5	Jayaraman S and Jarnagin WR: Management of gallbladder cancer. Gastroenterol Clin North Am. 39:331–342. 2010. View Article : Google Scholar : PubMed/NCBI
6	Kishimoto T: Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther. 8(Suppl 2): 22006. View Article : Google Scholar
7	Qi J, Chen N, Wang J and Siu CH: Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. Mol Biol Cell. 16:4386–4397. 2005. View Article : Google Scholar : PubMed/NCBI
8	Di GH, Liu Y, Lu Y, Liu J, Wu C and Duan HF: IL-6 secreted from senescent mesenchymal stem cells promotes proliferation and migration of breast cancer cells. PLoS One. 9:e1135722014. View Article : Google Scholar : PubMed/NCBI
9	Soubrane C, Rixe O, Meric JB, Khayat D and Mouawad R: Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res. 15:199–204. 2005. View Article : Google Scholar : PubMed/NCBI
10	Ataie-Kachoie P, Pourgholami MH and Morris DL: Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev. 24:163–173. 2013. View Article : Google Scholar
11	Sullivan NJ, Sasser AK, Axel AE, et al: Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene. 28:2940–2947. 2009. View Article : Google Scholar : PubMed/NCBI
12	Na YR, Lee JS, Lee SJ and Seok SH: Interleukin-6-induced Twist and N-cadherin enhance melanoma cell metastasis. Melanoma Res. 23:434–443. 2013. View Article : Google Scholar : PubMed/NCBI
13	Thiery JP: Epithelial-mesencymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
14	Liu AN, Zhu ZH, Chang SJ and Hang XS: Twist expression associated with the epithelial-mesenchymal transition in gastric cancer. Mol Cell Biochem. 367:195–203. 2012. View Article : Google Scholar : PubMed/NCBI
15	Qin Y, Zhang S, Gong W, Li J, Jia J and Quan Z: Adenovirus-mediated gene transfer of tissue factor pathway inhibitor-2 inhibits gallbladder carcinoma growth in vitro and in vivo. Cancer Sci. 103:723–730. 2012. View Article : Google Scholar : PubMed/NCBI
16	Diehl S, Anguita J, Hoffmeyer A, et al: Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity. 13:805–815. 2000. View Article : Google Scholar
17	Luo F, Xu Y, Ling M, et al: Arsenite evokes IL-6 secretion, autocrine regulation of STAT3 signaling and miR-21 expression, processes involved in the EMT and malignant transformation of human bronchial epithelial cells. Toxicol Appl Pharmacol. 273:27–34. 2013. View Article : Google Scholar : PubMed/NCBI
18	Wang Y, Qu Y, Zhang XL, et al: Autocrine production of interleukin-6 confers ovarian cancer cells resistance to tamoxifen via ER isoforms and SRC-1. Mol Cell Endocrinol. 2013.
19	Yeh KY, Li YY, Hsieh LL, et al: Analysis of the effect of serum interleukin-6 (IL-6) and soluble IL-6 receptor levels on survival of patients with colorectal cancer. Jpn J Clin Oncol. 40:580–587. 2010. View Article : Google Scholar : PubMed/NCBI
20	Duffy SA, Taylor JM, Terrell JE, et al: Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 113:750–757. 2008. View Article : Google Scholar : PubMed/NCBI
21	Suh SY, Choi YS, Yeom CH, et al: Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer. Support Care Cancer. 21:3071–3077. 2013. View Article : Google Scholar : PubMed/NCBI
22	Chang CH, Hsiao CF, Yeh YM, et al: Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer. 132:1977–1985. 2013. View Article : Google Scholar
23	Yu H, Kortylewski M and Pardoll D: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar
24	Ho PL, Lay EJ, Jian W, Parra D and Chan KS: Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res. 72:3135–3142. 2012. View Article : Google Scholar : PubMed/NCBI
25	Rathinavelu A, Narasimhan M and Muthumani P: A novel regulation of VEGF expression by HIF-1α and STAT3 in HDM2 transfected prostate cancer cells. J Cell Mol Med. 16:1750–1757. 2012. View Article : Google Scholar
26	Yadav A, Kumar B, Datta J, Teknos TN and Kumar P: IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res. 9:1658–1667. 2011. View Article : Google Scholar : PubMed/NCBI
27	de Freitas Silva BS, Yamamoto-Silva FP, Pontes HA and Pinto Júnior DS: E-cadherin downregulation and Twist overexpression since early stages of oral carcinogenesis. J Oral Pathol Med. 43:125–31. 2013. View Article : Google Scholar : PubMed/NCBI
28	Yuen HF, Chua CW, Chan YP, Wong YC, Wang X and Chan KW: Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology. 50:648–658. 2007. View Article : Google Scholar : PubMed/NCBI
29	Shibata K, Kajiyama H, Ino K, et al: Twist expression in patients with cervical cancer is associated with poor disease outcome. Ann Oncol. 19:81–85. 2008. View Article : Google Scholar
30	Zhao Z, Ge J, Sun Y, et al: Is E-cadherin immunoexpression a prognostic factor for head and neck squamous cell carcinoma (HNSCC)? A systematic review and meta-analysis. Oral Oncol. 48:761–767. 2012. View Article : Google Scholar : PubMed/NCBI
31	Bačić B, Haller H, Mrklić I, Košta V, Čarić A and Tomić S: Prognostic role of E-cadherin in patients with advanced serous ovarian cancer. Arch Gynecol Obstet. 287:1219–1224. 2013. View Article : Google Scholar
32	Aamodt R, Bondi J, Andersen SN, Bakka A, Bukholm G and Bukholm IR: The prognostic impact of protein expression of E-cadherin-catenin complexes differs between rectal and colon carcinoma. Gastroenterol Res Pract. 2010. View Article : Google Scholar : PubMed/NCBI
33	Shinriki S, Jono H, Ota K, et al: Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res. 15:5426–5434. 2009. View Article : Google Scholar : PubMed/NCBI
34	Guo Y, Xu F, Lu T, Duan Z and Zhang Z: Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 38:904–10. 2012. View Article : Google Scholar : PubMed/NCBI